In personalised medicine, the focus lies on adapting the treatment strategy to the individual patient. Therefore, it is necessary to analyse the specific features and characteristics of the tumour in order to identify the best possible therapy. In addition, some of this information can also be used to detect a tumour at an early stage or to perform tumour screening in asymptomatic individuals.
Datar Cancer Genetics has made it its business to offer solutions especially in advanced stages or for solid tumours that are difficult to treat (e.g. breast cancer, prostate cancer). At the same time, we are aware that the early detection of a cancer leads much more frequently to successful treatment, for example in the case of colorectal cancer or ovarian carcinoma. Much information is available in the blood, the analysis of which, in combination with advanced AI, helps to optimise therapy. Based on clinical studies over the past years, Datar Cancer Genetics has been able to develop evidence-based testing procedures both in the field of therapy management and in cancer screening. In total, more than 40,000 patients have been included in our studies to date, making a significant contribution to cancer diagnostics and therapy.
We are a leading molecular oncology facility with over 250 employees worldwide. We have laboratories in the UK and India, an in-house bioinformatics team and a comprehensive database that enables reporting according to the latest scientific standards.
Our laboratories are accredited by NABL, ISO 15189, CAP and CLIA. We work with research institutes, hospitals and physicians worldwide, e.g. from the USA, UK, India and the EU.